Circulating growth factor levels are associated with tumorigenesis in neurofibromatosis type 1

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
George A MashourAndreas Kurtz

Abstract

Neurofibromatosis type 1 (NF1) is characterized by systemic development of neurofibromas. Early clinical diagnosis can be ambiguous, and genetic diagnosis can be prohibitively difficult. Dysregulation of a number of growth factors has been suggested to be a mechanism of pathogenesis. This study was performed to assess the contribution of circulating growth factors for diffuse tumorigenesis and the diagnostic value of circulating growth factor identification in serum. The growth stimulation of neurofibroma-derived cells by serum from NF1 patients was tested, and serum growth factor levels in a cohort of NF1 patients (n = 39) between the ages of 7 and 70 years were analyzed. Concentrations of midkine (MK) and stem cell factor, but not epidermal growth factor, were substantially increased in serum of NF1 patients when compared with healthy controls. Within the NF1 group, MK levels increased dramatically at puberty from an average of 0.79 ng/mL in patients <18 years to 1.18 ng/mL in patients >18 years old. Stem cell factor and MK concentrations above a defined threshold in serum of NF1 patients are of diagnostic benefit for 96% of patients in the cohort tested. Furthermore, serum from NF1 patients enhanced proliferation of human ne...Continue Reading

References

Jun 1, 1992·Developmental Biology·D E WilliamsS D Lyman
Nov 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·D H GutmannF S Collins
Jun 14, 1991·Biochemical and Biophysical Research Communications·H Muramatsu, T Muramatsu
Mar 1, 1990·Annals of Neurology·N RatnerD M Hong
Jul 1, 1984·Annals of Neurology·R J RiopelleM C Martin
Jul 1, 1981·Archives of Neurology·R N Fabricant, G J Todaro
Jan 1, 1997·British Journal of Cancer·K KadomatsuT Muramatsu
Nov 5, 1997·Neuroscience Letters·K MishimaT Kirino
Jun 10, 1998·The Journal of Experimental Medicine·Y Y ZhangD W Clapp
Sep 1, 1999·The Journal of Investigative Dermatology·G A MashourA Kurtz
Aug 23, 2000·British Journal of Cancer·S IkematsuT Muramatsu
Dec 18, 2001·Nature Genetics·Hai YanBert Vogelstein
Feb 19, 2002·Journal of Immunoassay & Immunochemistry·Patrick SouliéJosé Courty
Sep 6, 2002·Genetic Epidemiology·J SzudekJ M Friedman
Oct 31, 2002·Journal of Child Neurology·Andreas Kurtz, Robert L Martuza
Mar 8, 2003·Proceedings of the National Academy of Sciences of the United States of America·John B WelshGarret M Hampton

❮ Previous
Next ❯

Citations

Sep 4, 2009·Journal of Pediatric Hematology/oncology·Susanne LucasPablo Hernáiz Driever
Jul 6, 2011·BMC Medicine·Mateusz KolanczykLan Kluwe
Sep 17, 2015·Pediatric Blood & Cancer·Michael J FergusonShi Chen
Jul 1, 2011·Journal of Pediatric and Adolescent Gynecology·Josh C SkorupskiElisabeth H Quint
Mar 14, 2007·Clinica Chimica Acta; International Journal of Clinical Chemistry·Pei-Wen WangYu-Ray Chen
Jul 25, 2008·Proteomics·Takashi Muramatsu, Hisako Muramatsu
Jan 13, 2011·Pediatric Blood & Cancer·Trent HummelBrian Weiss
May 23, 2009·Pediatrics International : Official Journal of the Japan Pediatric Society·Susanne LucasPablo Hernáiz Driever
Jun 9, 2016·Free Radical Biology & Medicine·Waylan K BesslerBrian K Stansfield
Jul 28, 2016·Cancer Immunology, Immunotherapy : CII·Said FarschtschiAndreas Kurtz
Sep 23, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Haiyan QinXiaofeng Huang
Jul 3, 2018·Oncotarget·Elizabeth A BrettDominik Duscher
Dec 22, 2016·CNS Oncology·Souvik Karmakar, Karlyne M Reilly

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.